SGI
KRYS icon

Summit Global Investments’s Krystal Biotech KRYS Stock Holding History

Summit Global Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,547
Closed -$625K – 518
2025
Q2 		$625K Sell
4,547
-164
-3% -$24.1K 0.04% 269
2025
Q1 		$849K Buy
4,711
+1,258
+36% +$212K 0.06% 193
2024
Q4 		$541K Buy
+3,453
New +$613K 0.03% 348

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Summit Global Investments's KRYS Position: Q3 2025 in Review

Summit Global Investments sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 4,547 shares — an estimated $625K sold.

Summit Global Investments first reported a position in KRYS in Q4 2024 and held it in 3 quarters. The position peaked at $849K in Q1 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Summit Global Investments reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Summit Global Investments sold 4,547 Krystal Biotech shares in Q3 2025, an estimated $625K.
  • Summit Global Investments first reported a position in Krystal Biotech in Q4 2024 and held it in 3 quarters.
  • Summit Global Investments's Krystal Biotech position peaked at $849K in Q1 2025.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Summit Global Investments's 13F filing for Q3 2025, filed 3 Nov 2025.